Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Vernon Holers to Complement C3

This is a "connection" page, showing publications Vernon Holers has written about Complement C3.

 
Connection Strength
 
 
 
4.578
 
  1. Banda NK, Mehta G, Kjaer TR, Takahashi M, Schaack J, Morrison TE, Thiel S, Arend WP, Holers VM. Essential role for the lectin pathway in collagen antibody-induced arthritis revealed through use of adenovirus programming complement inhibitor MAp44 expression. J Immunol. 2014 Sep 01; 193(5):2455-68.
    View in: PubMed
    Score: 0.435
  2. Holers VM. Human C3 glomerulopathy provides unique insights into complement factor H-related protein function. J Clin Invest. 2013 Jun; 123(6):2357-60.
    View in: PubMed
    Score: 0.401
  3. Kang HJ, Bao L, Xu Y, Quigg RJ, Giclas PC, Holers VM. Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects. Clin Exp Immunol. 2004 May; 136(2):194-9.
    View in: PubMed
    Score: 0.214
  4. Fahnoe KC, Liu F, Morgan JG, Ryan ST, Storek M, Stark EG, Taylor FR, Holers VM, Thurman JM, Wawersik S, Kalled SL, Violette SM. Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue. Front Immunol. 2022; 13:869725.
    View in: PubMed
    Score: 0.188
  5. Schriek P, Ching AC, Moily NS, Moffat J, Beattie L, Steiner TM, Hosking LM, Thurman JM, Holers VM, Ishido S, Lahoud MH, Caminschi I, Heath WR, Mintern JD, Villadangos JA. Marginal zone B cells acquire dendritic cell functions by trogocytosis. Science. 2022 02 11; 375(6581):eabf7470.
    View in: PubMed
    Score: 0.183
  6. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002 Jan 21; 195(2):211-20.
    View in: PubMed
    Score: 0.183
  7. Okamoto T, Mathai SK, Hennessy CE, Hancock LA, Walts AD, Stefanski AL, Brown KK, Lynch DA, Cosgrove GP, Groshong SD, Cool CD, Schwarz MI, Banda NK, Thurman JM, Yang IV, Holers VM, Schwartz DA. The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2018 07 01; 315(1):L1-L10.
    View in: PubMed
    Score: 0.140
  8. Quigg RJ, Alexander JJ, Lo CF, Lim A, He C, Holers VM. Characterization of C3-binding proteins on mouse neutrophils and platelets. J Immunol. 1997 Sep 01; 159(5):2438-44.
    View in: PubMed
    Score: 0.135
  9. Willis VC, Banda NK, Cordova KN, Chandra PE, Robinson WH, Cooper DC, Lugo D, Mehta G, Taylor S, Tak PP, Prinjha RK, Lewis HD, Holers VM. Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis. Clin Exp Immunol. 2017 05; 188(2):263-274.
    View in: PubMed
    Score: 0.130
  10. Chen F, Wang G, Griffin JI, Brenneman B, Banda NK, Holers VM, Backos DS, Wu L, Moghimi SM, Simberg D. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat Nanotechnol. 2017 05; 12(4):387-393.
    View in: PubMed
    Score: 0.128
  11. Laskowski J, Renner B, Le Quintrec M, Panzer S, Hannan JP, Ljubanovic D, Ruseva MM, Borza DB, Antonioli AH, Pickering MC, Holers VM, Thurman JM. Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. Kidney Int. 2016 07; 90(1):109-22.
    View in: PubMed
    Score: 0.123
  12. Inturi S, Wang G, Chen F, Banda NK, Holers VM, Wu L, Moghimi SM, Simberg D. Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. ACS Nano. 2015 Nov 24; 9(11):10758-68.
    View in: PubMed
    Score: 0.118
  13. Holers VM. Targeting mechanisms at sites of complement activation for imaging and therapy. Immunobiology. 2016 06; 221(6):726-32.
    View in: PubMed
    Score: 0.114
  14. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Fr?meaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodr?guez de C?rdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT. C3 glomerulopathy: consensus report. Kidney Int. 2013 Dec; 84(6):1079-89.
    View in: PubMed
    Score: 0.103
  15. Banda NK, Mehta G, Ferreira VP, Cortes C, Pickering MC, Pangburn MK, Arend WP, Holers VM. Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis. J Immunol. 2013 Apr 01; 190(7):3560-9.
    View in: PubMed
    Score: 0.098
  16. Levy E, Ambrus J, Kahl L, Molina H, Tung K, Holers VM. T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1992 Nov; 90(2):235-44.
    View in: PubMed
    Score: 0.096
  17. Holers VM, Kinoshita T, Molina H. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol Today. 1992 Jun; 13(6):231-6.
    View in: PubMed
    Score: 0.094
  18. Risitano AM, Notaro R, Pascariello C, Sica M, del Vecchio L, Horvath CJ, Fridkis-Hareli M, Selleri C, Lindorfer MA, Taylor RP, Luzzatto L, Holers VM. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28; 119(26):6307-16.
    View in: PubMed
    Score: 0.093
  19. Thurman JM, Tchepeleva SN, Haas M, Panzer S, Boackle SA, Glogowska MJ, Quigg RJ, Holers VM. Complement alternative pathway activation in the autologous phase of nephrotoxic serum nephritis. Am J Physiol Renal Physiol. 2012 Jun 15; 302(12):F1529-36.
    View in: PubMed
    Score: 0.093
  20. Carel JC, Myones BL, Frazier B, Holers VM. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem. 1990 Jul 25; 265(21):12293-9.
    View in: PubMed
    Score: 0.082
  21. Carel JC, Frazier B, Ley TJ, Holers VM. Analysis of epitope expression and the functional repertoire of recombinant complement receptor 2 (CR2/CD21) in mouse and human cells. J Immunol. 1989 Aug 01; 143(3):923-30.
    View in: PubMed
    Score: 0.077
  22. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008 Dec 01; 181(11):8068-76.
    View in: PubMed
    Score: 0.073
  23. Clark A, Weymann A, Hartman E, Turmelle Y, Carroll M, Thurman JM, Holers VM, Hourcade DE, Rudnick DA. Evidence for non-traditional activation of complement factor C3 during murine liver regeneration. Mol Immunol. 2008 Jun; 45(11):3125-32.
    View in: PubMed
    Score: 0.070
  24. Kuhn KA, Cozine CL, Tomooka B, Robinson WH, Holers VM. Complement receptor CR2/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collagen and citrullinated antigens. Mol Immunol. 2008 May; 45(10):2808-19.
    View in: PubMed
    Score: 0.070
  25. Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007 Dec 01; 179(11):7860-7.
    View in: PubMed
    Score: 0.068
  26. Twohig J, Kulik L, Haluszczak C, Reuter J, Rossbach A, Bull M, Holers VM, Marchbank KJ. Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21) transgenic mice is partially recovered in the absence of C3. Mol Immunol. 2007 Jul; 44(13):3434-44.
    View in: PubMed
    Score: 0.065
  27. Schepers A, de Vries MR, van Leuven CJ, Grimbergen JM, Holers VM, Daha MR, van Bockel JH, Quax PH. Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice. Circulation. 2006 Dec 19; 114(25):2831-8.
    View in: PubMed
    Score: 0.064
  28. Banda NK, Thurman JM, Kraus D, Wood A, Carroll MC, Arend WP, Holers VM. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J Immunol. 2006 Aug 01; 177(3):1904-12.
    View in: PubMed
    Score: 0.062
  29. Li Y, Jacques S, Gaikwad H, Wang G, Banda NK, Holers VM, Scheinman RI, Tomlinson S, Moghimi SM, Simberg D. Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins. Nat Nanotechnol. 2024 Feb; 19(2):246-254.
    View in: PubMed
    Score: 0.051
  30. Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, Quigg RJ. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol. 2003 Mar; 14(3):670-9.
    View in: PubMed
    Score: 0.049
  31. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003 Feb 01; 170(3):1517-23.
    View in: PubMed
    Score: 0.049
  32. Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus. 2003; 12(7):535-8.
    View in: PubMed
    Score: 0.049
  33. Fleming SD, Shea-Donohue T, Guthridge JM, Kulik L, Waldschmidt TJ, Gipson MG, Tsokos GC, Holers VM. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol. 2002 Aug 15; 169(4):2126-33.
    View in: PubMed
    Score: 0.047
  34. Wahid AA, Dunphy RW, Macpherson A, Gibson BG, Kulik L, Whale K, Back C, Hallam TM, Alkhawaja B, Martin RL, Meschede I, Laabei M, Lawson ADG, Holers VM, Watts AG, Crennell SJ, Harris CL, Marchbank KJ, van den Elsen JMH. Insights Into the Structure-Function Relationships of Dimeric C3d Fragments. Front Immunol. 2021; 12:714055.
    View in: PubMed
    Score: 0.044
  35. Springall T, Sheerin NS, Abe K, Holers VM, Wan H, Sacks SH. Epithelial secretion of C3 promotes colonization of the upper urinary tract by Escherichia coli. Nat Med. 2001 Jul; 7(7):801-6.
    View in: PubMed
    Score: 0.044
  36. Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol. 2001 May 15; 166(10):6444-51.
    View in: PubMed
    Score: 0.044
  37. Cunningham PN, Holers VM, Alexander JJ, Guthridge JM, Carroll MC, Quigg RJ. Complement is activated in kidney by endotoxin but does not cause the ensuing acute renal failure. Kidney Int. 2000 Oct; 58(4):1580-7.
    View in: PubMed
    Score: 0.042
  38. Frid MG, McKeon BA, Thurman JM, Maron BA, Li M, Zhang H, Kumar S, Sullivan T, Laskowsky J, Fini MA, Hu S, Tuder RM, Gandjeva A, Wilkins MR, Rhodes CJ, Ghataorhe P, Leopold JA, Wang RS, Holers VM, Stenmark KR. Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. Am J Respir Crit Care Med. 2020 01 15; 201(2):224-239.
    View in: PubMed
    Score: 0.040
  39. Rich MC, Keene CN, Neher MD, Johnson K, Yu ZX, Ganivet A, Holers VM, Stahel PF. Site-targeted complement inhibition by a complement receptor 2-conjugated inhibitor (mTT30) ameliorates post-injury neuropathology in mouse brains. Neurosci Lett. 2016 Mar 23; 617:188-94.
    View in: PubMed
    Score: 0.030
  40. Neher MD, Rich MC, Keene CN, Weckbach S, Bolden AL, Losacco JT, Patane J, Flierl MA, Kulik L, Holers VM, Stahel PF. Deficiency of complement receptors CR2/CR1 in Cr2?/? mice reduces the extent of secondary brain damage after closed head injury. J Neuroinflammation. 2014 May 24; 11:95.
    View in: PubMed
    Score: 0.027
  41. Li B, Sallee C, Dehoff M, Foley S, Molina H, Holers VM. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol. 1993 Oct 15; 151(8):4295-305.
    View in: PubMed
    Score: 0.026
  42. Foley S, Li B, Dehoff M, Molina H, Holers VM. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Eur J Immunol. 1993 Jun; 23(6):1381-4.
    View in: PubMed
    Score: 0.025
  43. Strassheim D, Renner B, Panzer S, Fuquay R, Kulik L, Ljubanovic D, Holers VM, Thurman JM. IgM contributes to glomerular injury in FSGS. J Am Soc Nephrol. 2013 Feb; 24(3):393-406.
    View in: PubMed
    Score: 0.025
  44. Elvington A, Atkinson C, Kulik L, Zhu H, Yu J, Kindy MS, Holers VM, Tomlinson S. Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol. 2012 Feb 01; 188(3):1460-8.
    View in: PubMed
    Score: 0.023
  45. Khan MA, Jiang X, Dhillon G, Beilke J, Holers VM, Atkinson C, Tomlinson S, Nicolls MR. CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011 Nov 11; 109(11):1290-301.
    View in: PubMed
    Score: 0.022
  46. Banda NK, Levitt B, Wood AK, Takahashi K, Stahl GL, Holers VM, Arend WP. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro. Clin Exp Immunol. 2010 Jan; 159(1):100-8.
    View in: PubMed
    Score: 0.020
  47. Holers VM. Complement receptors. Year Immunol. 1989; 4:231-40.
    View in: PubMed
    Score: 0.018
  48. McNearney TA, Odell C, Holers VM, Spear PG, Atkinson JP. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J Exp Med. 1987 Nov 01; 166(5):1525-35.
    View in: PubMed
    Score: 0.017
  49. Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J Immunol. 2007 Sep 15; 179(6):4101-9.
    View in: PubMed
    Score: 0.017
  50. Holers VM, Chaplin DD, Leykam JF, Gruner BA, Kumar V, Atkinson JP. Human complement C3b/C4b receptor (CR1) mRNA polymorphism that correlates with the CR1 allelic molecular weight polymorphism. Proc Natl Acad Sci U S A. 1987 Apr; 84(8):2459-63.
    View in: PubMed
    Score: 0.016
  51. Yu GH, Holers VM, Seya T, Ballard L, Atkinson JP. Identification of a third component of complement-binding glycoprotein of human platelets. J Clin Invest. 1986 Aug; 78(2):494-501.
    View in: PubMed
    Score: 0.016
  52. Li S, Boackle SA, Holers VM, Lambris JD, Blatteis CM. Complement component c5a is integral to the febrile response of mice to lipopolysaccharide. Neuroimmunomodulation. 2005; 12(2):67-80.
    View in: PubMed
    Score: 0.014
  53. Ohta R, Kondor N, Dohi N, Tomlinson S, Imai M, Holers VM, Okada H, Okada N. Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity in vivo. J Immunol. 2004 Jul 01; 173(1):205-13.
    View in: PubMed
    Score: 0.014
  54. M?hlfeld AS, Segerer S, Hudkins K, Farr AG, Bao L, Kraus D, Holers VM, Quigg RJ, Alpers CE. Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. Kidney Int. 2004 Apr; 65(4):1214-23.
    View in: PubMed
    Score: 0.013
  55. Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 2004 Jan; 65(1):129-38.
    View in: PubMed
    Score: 0.013
  56. Song H, He C, Knaak C, Guthridge JM, Holers VM, Tomlinson S. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest. 2003 Jun; 111(12):1875-85.
    View in: PubMed
    Score: 0.013
  57. Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol. 2002 Apr 01; 168(7):3601-7.
    View in: PubMed
    Score: 0.012
  58. Park P, Haas M, Cunningham PN, Alexander JJ, Bao L, Guthridge JM, Kraus DM, Holers VM, Quigg RJ. Inhibiting the complement system does not reduce injury in renal ischemia reperfusion. J Am Soc Nephrol. 2001 Jul; 12(7):1383-1390.
    View in: PubMed
    Score: 0.011
  59. Schiller B, Cunningham PN, Alexander JJ, Bao L, Holers VM, Quigg RJ. Expression of a soluble complement inhibitor protects transgenic mice from antibody-induced acute renal failure. J Am Soc Nephrol. 2001 Jan; 12(1):71-79.
    View in: PubMed
    Score: 0.011
  60. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H. A critical role for murine complement regulator crry in fetomaternal tolerance. Science. 2000 Jan 21; 287(5452):498-501.
    View in: PubMed
    Score: 0.010
  61. Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol. 2000 Jan 15; 164(2):786-94.
    View in: PubMed
    Score: 0.010
  62. Kawamoto Y, Kojima K, Hitsumoto Y, Okada H, Holers VM, Miyama A. The serum resistance of malaria-infected erythrocytes. Immunology. 1997 May; 91(1):7-12.
    View in: PubMed
    Score: 0.008
  63. Sawant-Mane S, Piddlesden SJ, Morgan BP, Holers VM, Koski CL. CD59 homologue regulates complement-dependent cytolysis of rat Schwann cells. J Neuroimmunol. 1996 Sep; 69(1-2):63-71.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)